Brian Park, PharmD

Drug Information Specialist https://www.rheumatologyadvisor.com

Brian Park, PharmD, is a Drug Information Specialist at MPR. A graduate of the Ernest Mario School of Pharmacy, Rutgers University, Brian worked as a pharmacy manager at Stop & Shop Pharmacy for 8 years. He is a certified diabetes care pharmacist.

All articles by Brian Park, PharmD

General Rheumatology

NIH: Hydroxychloroquine Not Effective for COVID-19

By

Brian Park, PharmD

November 17, 2020

The ORCHID trial was halted in June 2020 after it was determined that hydroxychloroquine was unlikely to benefit hospitalized patients.

Spondyloarthritis

Secukinumab Associated With Reduced Synovitis in Psoriatic Arthritis

By

Brian Park, PharmD

November 13, 2020

The 52-week double-blind, placebo-controlled ULTIMATE study included 166 adult biologic-naive patients with active psoriatic arthritis.

General Rheumatology

NIH: Immune Modulators to Be Investigated for COVID-19

By

Brian Park, PharmD

October 23, 2020

The NIH-led trial will assess 3 drugs: infliximab, a tumor necrosis factor blocker, abatacept, a selective T cell costimulation modulator, and cenicriviroc, an investigational immunomodulator that blocks 2 chemokine receptors, CCR2 and CCR5.

General Rheumatology

Trial Evaluating Anti-SARS-CoV-2 Hyperimmune Globulin Begins

By

Brian Park, PharmD

October 15, 2020

The antibody solution is derived from plasma donated by healthy individuals who have recovered from COVID-19.

General Rheumatology

Emergency Use Authorization Guidance Issued for COVID-19 Vaccines

By

Brian Park, PharmD

October 14, 2020

The FDA has issued recommendations regarding the issuance of emergency use authorization for investigational COVID-19 vaccines.

Pediatric Rheumatology

Golimumab Approved for Polyarticular JIA, Pediatric Psoriatic Arthritis

By

Brian Park, PharmD

October 5, 2020

The FDA has approved Simponi Aria for the treatment of patients aged 2 years and older with active polyarticular juvenile idiopathic arthritis.

General Rheumatology

Phase 3 Trial of Janssen’s COVID-19 Vaccine to Evaluate Single Dose Regimen

By

Brian Park, PharmD

October 5, 2020

A phase 3 trial evaluating the vaccine candidate, JNJ-78436735 (Ad26.COV2.S; Janssen), for the prevention of COVID-19 has been initiated.

hands of a child with juvenile idiopathic arthritis

Pediatric Rheumatology

FDA Approves Tofacitinib for the Treatment of Active Polyarticular Course Juvenile Idiopathic Arthritis

By

Brian Park, PharmD

October 1, 2020

Patients treated with tofacitinib experienced significantly fewer disease flares compared with placebo.

General Rheumatology

Point-of-Care COVID-19 Antibody Test Gets Emergency Use Authorization

By

Brian Park, PharmD

September 30, 2020

The FDA has issued an Emergency Use Authorization (EUA) for Assure COVID-19 IgG/IgM Rapid Test Device.

General Rheumatology

Trials Testing Convalescent Plasma for COVID-19 Expanded

By

Brian Park, PharmD

September 30, 2020

Both randomized, placebo-controlled trials are expected to enroll approximately 1000 hospitalized patients.

Next post in General Rheumatology

doctors looking at patient on a gurney

New Score Can Identify Patients at High Risk for Severe COVID-19